Acotec Scientific Holdings Limited 6669.HK Stock

Acotec Scientific Holdings Limited, a medical device company, engages in the research and development of percutaneous transluminal angioplasty and drug-coated balloon products for the treatment of vascular diseases in Mailand China, Europe, and internationally. It offers AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease, under clinical studies in nephrology for arteriovenous fistula stenosis and in neurology for vertebral atherosclerotic stenosis indications/applications, and under clinical studies in andrology for vasculogenic erectile dysfunction indications/applications. The company also provides AcoArt Tulip & Litos, a paclitaxel DCB used to prevent stenosis or occlusion in below-the-knee arteries for the treatment of chronic limb-threatening ischemia, and in pre-clinical studies in andrology for vasculogenic erectile dysfunction indications/applications. The company was founded in 2011 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of CA Medtech Investment (Cayman) Limited. As of February 20, 2023, Acotec Scientific Holdings Limited operates as a subsidiary of Boston Scientific Group Public Limited Company.